{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.6","value":"3.6"},{"groupId":"OG001","spread":"4.1","value":"3.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"74"}],"units":"Participants"}],"title":"In a clinic or hospital emergency room for any health issue including MM"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.3","value":"4.4"},{"groupId":"OG001","spread":"4.2","value":"4.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"52"}],"units":"Participants"}],"title":"In a clinic or hospital emergency room due to MM"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.4","value":"4.4"},{"groupId":"OG001","spread":"3.2","value":"3.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"26"}],"units":"Participants"}],"title":"At-home from nurse or other health professional for any health issue including MM"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.9","value":"4.7"},{"groupId":"OG001","spread":"3.6","value":"3.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"title":"At-home from nurse or other health professional due to MM"}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"74"}],"units":"Participants"}],"description":"Healthcare utilization at baseline before study medication administration was collected via HRUPQ. The mean number of times in the past 6 months a participant received care in a clinic or hospital emergency room for any health issue including MM or due to MM and at-home care from a nurse or other health professional for any health issue including MM or due to MM is presented. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received isatuximab 10 mg/kg IV infusion QW (i.e. on Days 1, 8, 15 and 22) in Cycle 1 (28 days) and then 10 mg/kg Q2W (i.e. on Days 1 and 15) of each subsequent 28-day cycle along with pomalidomide 4 mg orally on Days 1 to 21 of each 28-day cycle and dexamethasone 40 mg (or 20 mg for participant \\>=75 years) orally on Days 1, 8, 15, and 22 of each cycle until disease progression, unacceptable AEs, participant request to discontinue treatment, or any other reason, whichever came first.","id":"OG000","title":"Isa-IV + Pd"},{"description":"Participants received isatuximab 1400 mg SC injection administered via an OBDS which is an investigational device injector QW (i.e on Days 1, 8, 15 and 22) in Cycle 1 (28 days) and then 1400 mg Q2W (i.e. on Days 1 and 15) of each subsequent 28-day cycle along with pomalidomide 4 mg orally on Days 1 to 21 of each 28-day cycle and dexamethasone 40 mg (or 20 mg for participant \\>=75 years) orally on Days 1, 8, 15, and 22 of each cycle until disease progression, unacceptable AEs, participant request to discontinue treatment, or any other reason, whichever came first.","id":"OG001","title":"Isa-SC + Pd"}],"paramType":"MEAN","populationDescription":"The ITT population included all randomized population. Only those participants with responses at Baseline are presented.","reportingStatus":"POSTED","timeFrame":"Baseline (Cycle 1 Day 1)","title":"Health Resource Utilization and Productivity Questionnaire (HRUPQ): Baseline Healthcare Utilization: Number of Times in the Past 6 Months a Participant Received Care","type":"SECONDARY","unitOfMeasure":"number of times received care"}